Nuvectis Pharma, Inc.
NVCT
$6.49
-$0.38-5.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 75.41% | 8.76% | -24.91% | -7.89% | 12.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.04% | 26.66% | 9.94% | -29.21% | -19.56% |
| Operating Income | -42.04% | -26.66% | -9.94% | 29.21% | 19.56% |
| Income Before Tax | -43.04% | -27.84% | 5.65% | 29.38% | 22.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.04% | -27.84% | 5.65% | 29.38% | 22.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.04% | -27.84% | 5.65% | 29.38% | 22.42% |
| EBIT | -42.04% | -26.66% | -9.94% | 29.21% | 19.56% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -13.13% | -6.15% | 13.92% | 34.01% | 30.34% |
| Normalized Basic EPS | -13.13% | -6.16% | -1.38% | 34.01% | 30.30% |
| EPS Diluted | -13.13% | -6.15% | 13.92% | 34.01% | 30.34% |
| Normalized Diluted EPS | -13.13% | -6.16% | -1.38% | 34.01% | 30.30% |
| Average Basic Shares Outstanding | 26.42% | 20.40% | 9.61% | 6.99% | 11.35% |
| Average Diluted Shares Outstanding | 26.42% | 20.40% | 9.61% | 6.99% | 11.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |